Literature DB >> 23689616

Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.

Markus J Riemenschneider1, David N Louis, Michael Weller, Peter Hau.   

Abstract

Individualized therapies are popular current concepts in oncology and first steps towards stratified medicine have now been taken in neurooncology through implementation of stratified therapeutic approaches. Knowledge about the molecular basis of brain tumors has expanded greatly in recent years and a few molecular alterations are studied routinely because of their clinical relevance. However, no single targeted agent has yet been fully approved for the treatment of glial brain tumors. In this review, we argue that multidisciplinary and integrated approaches are essential for translational research and the development of new treatments for patients with malignant gliomas, and we present a conceptual framework in which to place the components of such an interdisciplinary approach. We believe that this ambitious goal can be best realized through strong cooperation of brain tumor centers with local hospitals and physicians; such an approach enables close dialogue between expert subspecialty clinicians and local therapists to consider all aspects of this increasingly complex set of diseases.

Entities:  

Mesh:

Year:  2013        PMID: 23689616     DOI: 10.1007/s00401-013-1127-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  7 in total

1.  Magnetic resonance imaging-guided stratified selection of patients for nano-therapy.

Authors:  Zhen Zheng; Gaolin Liang
Journal:  Ann Transl Med       Date:  2016-10

2.  [Molecular diagnostics in neuropathology].

Authors:  W Dietmaier; J Lorenz; M J Riemenschneider
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

3.  Expression and targeting of transcription factor ATF5 in dog gliomas.

Authors:  D York; C D Sproul; N Chikere; P J Dickinson; J M Angelastro
Journal:  Vet Comp Oncol       Date:  2017-05-08       Impact factor: 2.613

4.  [Personalized therapy for gliomas].

Authors:  W Wick; P Hau
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

Review 5.  Contemporary murine models in preclinical astrocytoma drug development.

Authors:  Robert S McNeill; Mark Vitucci; Jing Wu; C Ryan Miller
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

Review 6.  Oligodendroglioma: pathology, molecular mechanisms and markers.

Authors:  Pieter Wesseling; Martin van den Bent; Arie Perry
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

Review 7.  Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.

Authors:  Harry R Haynes; Sandra Camelo-Piragua; Kathreena M Kurian
Journal:  Front Oncol       Date:  2014-03-24       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.